Alcoholic liver disease (ALD)
- ALD is a continuum from fatty liver to steatohepatitis and liver cirrhosis.
- ALD increases the risk of hepatocellular carcinoma, and some patients develop acute alcoholic hepatitis resulting from a drinking spree.
- The risk limit for alcohol consumption is 20 g a day of absolute alcohol for women and 30 g for men – however, there are no completely safe limits for alcohol consumption.
- Binge drinking is harmful regardless of the average alcohol consumption.
- The aim is to recognize early stages of alcoholic liver disease, to stop alcohol consumption in time before the disease progresses and to treat complications of advanced disease.
- A person may have several risk factors for liver disease (such as alcohol and obesity), which should be treated simultaneously. Alcohol also speeds up the progression of liver damage from other causes (NAFLD, chronic viral hepatitis).
- See also the article Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)).
Examination and diagnosis
Examination and diagnosis
- For diagnosis, a history of high alcohol consumption and clinical or biological proof of liver damage is required.
- Alcohol history
- Proof of high alcohol consumption
- AUDIT test to assess alcohol consumption
- If the alcohol history remains uncertain or unreliable, other indicators can be used, as necessary.
- Direct alcohol markers (breath alcohol, serum ethanol, blood phosphatidylethanol)
- Indirect alcohol markers (AST/ALT ratio, MCV, CDT) are low in sensitivity and should therefore be combined with other laboratory tests, history and clinical findings
- See also Recognition of alcohol and drug abuse (Recognition of alcohol and drug abuse)
- Basic tests when suspecting ALD (Basic blood count with platelet count, plasma ALT, AST, ALP, bilirubin, prothrombin time or INR, albumin, serum prealbumin, plasma potassium, sodium, creatinine, and fasting glucose)
- Upper abdominal ultrasonography
- Tests for alternative or concomitant causes T1. See also article on Assessing patients with abnormal liver function test results (Assessing a patient with an abnormal liver function test result).
- Detecting concomitant risk factors for liver disease
- Family history of cirrhosis, obesity (Assessment of an obese patient), metabolic syndrome (Metabolic syndrome), diabetes (Comprehensive treatment and follow-up of type 2 diabetes), different types of viral hepatitis (Viral hepatitis), hepatotoxic medication (see locally available drug database), natural products and smoking
- Detecting alcoholic hepatitis
- Acute jaundice, liver failure, general symptoms, resulting from excessive drinking
- Patients with alcoholic hepatitis need emergency specialized care.
- Detecting liver cirrhosis
- See also Cirrhosis of the liver (Cirrhosis of the liver).
- Clinical signs of liver cirrhosis
- Spider naevi, palmar erythema, jaundice, ascites, muscular wasting
- Some patients with cirrhosis may be asymptomatic and may have normal liver enzyme values. Detecting such ‘silent’ cirrhosis is essential for the prognosis and for screening for complications particularly in heavy drinkers.
- Markers of fibrosis, Fibrosis-4 index (i.e. FIB-4 index https://www.mdcalc.com/fibrosis-4-fib-4-index-liver-fibrosis), aspartate aminotransferase to platelet ratio index (APRI, i.e. AST/platelet index https://www.mdcalc.com/ast-platelet-ratio-index-apri), should be used only after due consideration because they have not been separately validated for alcoholic liver disease, and alcohol consumption as such may lead to inaccurate values.
- Elastography (if available)
- Screening for complications
- Oesophageal varices (Haematemesis) (gastroscopy), hepatocellular carcinoma (Cancer of the liver and the biliary tract) (ultrasonography)
- Assessment of nutritional status
- The aim is to eat several meals a day, 35 kcal/kg/day of energy and 1.2–1.5 g/kg/day of protein.
- Detection of other diseases associated with ALD
- GI cancers (Colorectal cancer), cancers in the head and neck regions (Cancers of the head and neck), respiratory tract cancers (Lung cancer), alcohol-related neurological diseases (Neurological disorders and alcohol), dilated cardiomyopathy (Dilated cardiomyopathy), hypertension (Hypertension: investigations and starting treatment), arrhythmias (Symptoms of arrhythmia and examination of an arrhythmia patient)
- The most important treatment improving the prognosis is stopping alcohol consumption.
- This will improve the prognosis at any stage of the disease.
- It will reverse histological changes in the liver.
- A mini intervention (Brief interventions for risky use of alcohol) should be performed for all heavy users.
- Appropriate patients should be referred for substance abuse treatment (Providing care for an alcohol or drug abuser) (Drugs used in alcohol dependence)
- See also Pharmacotherapy in alcohol dependence (Drugs used in alcohol dependence).
- Management of concomitant risk factors of liver disease
- Weight reduction, avoiding medication and natural products that put a strain on the liver, smoking cessation
- Treatment plans for patients with mild disease should be made in primary health care.
- If drinking continues, about 20% of patients with ALD will develop cirrhosis.
- The aim of follow-up is to motivate patients to reduce their alcohol consumption and to detect any signs of progressive disease or complications requiring treatment.
Consulting specialized care
Consulting specialized care
- Specialized care should be consulted if the patient has signs of progressed disease.
- Clinical or biochemical signs, imaging or elastography
- In specialized care
- Confirming the diagnosis in unclear cases
- Elastography; liver biopsy, as necessary
- Planning the treatment of progressed disease and guidance for further follow-up in primary health care
- Exclusion of hepatocellular carcinoma (ultrasonography)
- Screening for, and treatment of, oesophageal varices (gastroscopy)
- Treatment of other complications of portal hypertension (ascites, encephalopathy, hepatorenal syndrome)
- Assessment of the possibility of liver transplantation in selected patients who were capable of stopping their alcohol consumption and whose liver cirrhosis remains decompensated (ascites, jaundice, encephalopathy, recurrent bleeding from oesophageal varices) despite abstinence
- Confirming the diagnosis in unclear cases
- Consultation of an addiction medicine specialist and a social worker
- The prognosis of patients with liver cirrhosis who continue to drink after appropriate primary assessment is very poor, and in most cases they do not benefit from follow-up in specialized care.
Table 1. Workup in patients with alcoholic liver disease
|Basic investigations||Differential diagnostic tests as considered appropriate||Assessment of severity||Finding complications in progressed disease|
|Basic blood count, ALT, AST, ALP, Bil, PT or INR, Alb, Prealb, potassium, sodium, creatinine and fasting glucose||HBsAg, anti-HCV antibodies, anti-smooth muscle antibodies, antimitochondrial antibodies, antinuclear antibodies, anti-transglutaminase antibodies, IgG, IgA, IgM, Fe, transferrin saturation level, ferritin, alpha1 antitrypsin||(APRI, FIB-4 fibrosis markers as considered appropriate)||Oesophageal varices|
|Upper abdominal ultrasonography||Elastography, if available||Hepatocellular cancer|
|In patients with cirrhosis, severity of disease based on the Child–Pugh scorehttps://www.mdcalc.com/child-pugh-score-cirrhosis-mortality||Ascites|
1. Singal AK, Bataller R, Ahn J et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol 2018;113(2):175-194. [PMID:29336434] https://journals.lww.com/ajg/fulltext/2018/02000/acg_clinical_guideline__a...
2. Crabb DW, Im GY, Szabo G et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2020;71(1):306-333. [PMID:31314133] https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30866
3. Thursz M, Kamath PS, Mathurin P et al. Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. J Hepatol 2019;70(3):521-530. [PMID:30658117] https://doi.org/10.1016/j.jhep.2018.10.041
4. European Association for the Study of the Liver. Electronic address: email@example.com., European Association for the Study of the Liver.. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018;69(1):154-181. [PMID:29628280] https://doi.org/10.1016/j.jhep.2018.03.018
5. Friedman SL. Management of alcohol-associated steatosis and alcohol-associated cirrhosis. UpToDate. https://www.uptodate.com/contents/management-of-alcohol-associated-steatosis-and-alcohol-associated-cirrhosis (accessed 16.10.2021) https://www.uptodate.com/contents/management-of-alcohol-associated-steatosis-and-alcohol-associated-cirrhosis/print...
6. Friedman SL. Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis. UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-alcohol-associated-fatty-liver-disease-and-cirrhosis (accessed 16.10.2021) https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-alcohol-associated-fatty-liver-disease-and-cirrhosis/print...
Copyright © 2023 Duodecim Medical Publications Limited.
Alcoholic liver disease (ALD) is a sample topic from the Evidence-Based Medicine Guidelines.
To view other topics, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.
"Alcoholic Liver Disease (ALD)." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305440/all/Alcoholic_liver_disease__ALD_.
Alcoholic liver disease (ALD). Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305440/all/Alcoholic_liver_disease__ALD_. Accessed March 22, 2023.
Alcoholic liver disease (ALD). (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305440/all/Alcoholic_liver_disease__ALD_
Alcoholic Liver Disease (ALD) [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305440/all/Alcoholic_liver_disease__ALD_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Alcoholic liver disease (ALD) ID - 1305440 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305440/all/Alcoholic_liver_disease__ALD_ PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -